Acrivon Therapeutics

ACRV

Market cap $61.2M

ACRV Hedge Fund Activity: Q1 2026 in Review

44 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2026, worth a combined $22.6M — down 50% from $44.9M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ACRV and 10 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 11 added.

The largest buyer was Acadian Asset Management, adding an estimated $462K. The largest seller was Citadel Advisors, exiting entirely with an estimated $3.96M sold.

• 44 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2026, down from 48 in Q4 2025.
• Funds reported $22.6M of Acrivon Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
• 10 funds opened new Acrivon Therapeutics positions in Q1 2026 and 13 closed out, a net change of -3 holders.
• The largest Acrivon Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $462K added.
• The largest Acrivon Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $3.96M sold.

Based on aggregated 13F filings for Q1 2026.